West Pharmaceutical Services stock sank Thursday after the company issued a full-year outlook that missed analysts’ ...

In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...

Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.

West Pharmaceutical Services Inc.’s stock tumbled 33% Thursday, to lead S&P 500 decliners, after the manufacturer of ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Shares of healthcare products company West Pharmaceutical Services (NYSE:WST) fell 34.9% in the afternoon session after the ...

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in ...

West Pharmaceutical reported Q4 earnings and revenue above expectations but issued a weak 2025 forecast. William Blair ...

Following the earnings announcement, WST stock plummeted 38% due to its disappointing guidance. Over a broader timeframe, its ...

Gilead Sciences (GILD) could open near nine-year highs after beating fourth-quarter earnings and revenue estimates ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...